IPA ImmunoPrecise Antibodies Ltd. Price Chart

This chart reflects the current market value of ImmunoPrecise Antibodies (IPA) at 2.07. ImmunoPrecise Antibodies (IPA) monetizes unique antibody selection software, leveraging pricing power by accelerating pharmaceutical development. The team brings together visionaries and scientists who value research freedom and stock options. Its Canadian status and alliances with US behemoths provide the firm with patent protection and immunity to trade conflicts.

IPA - ImmunoPrecise Antibodies Stock Price over the range 07/04/2022 - 09/04/2025

ImmunoPrecise (IPA) - metric breakdowns and financial figures

- stock quotes and analyst forecast:

Stock Price ImmunoPrecise Antibodies|IPA - Analyst Median Target

- market capitalization data:

Market Value ImmunoPrecise Antibodies Ltd|IPA - Full Business Value

- balance sheet equity data:

Book Value per Share ImmunoPrecise Antibodies|IPA - Book Capitalization|Market Capitalization to Book Value Ratio immunoprecise.com|IPA - Total Business Assets

- company total debt and liquidity indicators:

- earnings and market ratios statistics:

IPA - Net Income|Future Profit ImmunoPrecise Antibodies|IPA - P/E Multiple|Future Price to Earnings ImmunoPrecise Antibodies|IPA - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ImmunoPrecise Antibodies Ltd|IPA - Profit before interest, taxes and amortization|Earnings per share for the last twelve months ImmunoPrecise Antibodies|IPA - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months immunoprecise.com|IPA - Earnings per share increase in current year|Earnings growth forecast for next year ImmunoPrecise Antibodies

Comprehensive company analysis:ImmunoPrecise Antibodies Ltd.

Conservative capital requires asset valuation transparency to determine the margin of safety for a position relative to support levels. This indicator measures the market value of the security, allowing investors to assess the risk of a deep correction should sentiment shift, which is critical for ImmunoPrecise Antibodies (IPA) due to revenue dependence on the cyclical early-stage research spending of pharma behemoths. Analyzing stock price fluctuations on GURU.Markets helps align the current price with the resilience of the company's business model.

Main competitors